Analysis of efficacy and safety of vismodegib therapy in patients with advanced basal cell carcinoma – real world multicenter cohort study
In this medfyle
This retrospective analysis to assess the efficacy and safety of vismodegib in a cohort of 108 patients affected by mBCC and laBCC, shows overall efficacy results that are consistent with ERIVANCE and STEVIE studies, therapy was well tolerated, while female gender was described as an independent positive prognostic factor of PFS.
This Medfyle was published more than two years ago. More recent Medfyle on this topic may now be available.
Expert commentary
About this Medfyle
This Medfyle is provided as a service to healthcare professionals. It is a summary of an article originally published in the Journal of the European Academy of Dermatology and Venereology.
The summary was prepared by Marta Castano on behalf of Medfyle and reviewed by Eliana B. Souto, PhD.
Original article:
Słowińska M, Dudzisz-Śledź M, Sobczuk P, Łasińska I, Pietruszka A, Cybulska-Stopa B, Kowalczyk A, Świtaj T, Czarnecka I, Koseła-Paterczyk H, Rogala P, Paluchowska E, Składowski K, Mackiewicz J, Rutkowski P, Owczarek W. Analysis of efficacy and safety of vismodegib therapy in patients with advanced basal cell carcinoma - real world multicenter cohort study. J Eur Acad Dermatol Venereol. 2022 Aug;36(8):1219-1228.
The authors of the original article, the publisher, and the EADV were not involved in the creation of the summary.
